Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Ovarian Cancer

Clinical Trial at: Arizona Oncology - Phoenix

Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  • Details

ClinicalTrials.gov ID: NCT03522246
Diagnosis Type: NA
USOR Number: 17182

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Gastric Cancer

Clinical Trial at: Arizona Oncology - Tucson

CA209-577 - A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer

  • Details

ClinicalTrials.gov ID: NCT02743494
Diagnosis Type: NA
USOR Number: 18195

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Arizona Oncology - Phoenix

Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  • Details

ClinicalTrials.gov ID: NCT03522246
Diagnosis Type: NA
USOR Number: 17182

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Esophageal Cancer

Clinical Trial at: Arizona Oncology - Tucson

CA209-577 - A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer

  • Details

ClinicalTrials.gov ID: NCT02743494
Diagnosis Type: NA
USOR Number: 18195

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Leukemia

Clinical Trial at: Arizona Oncology - Tucson

A phase 3b study in previously untreated Chronic Lymphocytic Leukemia (CLL) subjects, excluding those with the 17p deletion, to evaluate debulking regimens prior to initiating venetoclax combination therapy (M16-788)

  • Details

ClinicalTrials.gov ID: NCT03406156
Diagnosis Type: CLL
USOR Number: 17106

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

  • Details

ClinicalTrials.gov ID: NCT03725059
Diagnosis Type: NA
USOR Number: 17188

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Leukemia

Clinical Trial at: Arizona Oncology - Tucson

Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

  • Details

ClinicalTrials.gov ID: NCT03268954
Diagnosis Type: NA
USOR Number: 17153

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Arizona Oncology - Phoenix

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

19646 N 27th Avenue, Suite 406
Phoenix, Arizona 85027
P: (602) 357-2400

More Details View Practice Page

Myelodysplastic Syndrome

Clinical Trial at: Arizona Oncology - Tucson

Pevonedistat-3001: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

  • Details

ClinicalTrials.gov ID: NCT03268954
Diagnosis Type: High Risk
USOR Number: 17153

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Arizona Oncology - Tucson

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

603 N Wilmot Rd, Suite 151
Tucson, Arizona 85711
P: (520) 886-0206

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

  • Details

ClinicalTrials.gov ID: NCT03053193
Diagnosis Type: NA
USOR Number: 17079

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Breast Cancer

Clinical Trial at: Arizona Oncology - Tucson

(I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

  • Details

ClinicalTrials.gov ID: NCT03155997
Diagnosis Type: NA
USOR Number: 17082

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Arizona Oncology - Glendale

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

7200 W Bell Road, Building A
Glendale, Arizona 85308
P: (623) 487-4822

More Details View Practice Page

Unlisted

Clinical Trial at: Arizona Oncology - Tucson

An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

  • Details

ClinicalTrials.gov ID: NCT02832167
Diagnosis Type: NA
USOR Number: 16041

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

GI Stromal Tumor (GIST)

Clinical Trial at: Arizona Oncology - Tucson

An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

  • Details

ClinicalTrials.gov ID: NCT03465722
Diagnosis Type: NA
USOR Number: 18016

  • Practice Details

2070 W Rudasill Rd, Suite 130
Tucson, Arizona 85704
P: (520) 797-4468

More Details View Practice Page

Lung Cancer

Clinical Trial at: Arizona Oncology - Scottsdale

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

  • Details

ClinicalTrials.gov ID: NCT03535740
Diagnosis Type: NSCLC
USOR Number: 18076

  • Practice Details

10460 N 92nd St, Suite 402
Scottsdale, Arizona 85258
P: (480) 860-2540

More Details View Practice Page

Lung Cancer

Clinical Trial at: Arizona Oncology - Tucson

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

  • Details

ClinicalTrials.gov ID: NCT03535740
Diagnosis Type: NSCLC
USOR Number: 18076

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Lymphomas

Clinical Trial at: Arizona Oncology - Phoenix

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

  • Details

ClinicalTrials.gov ID: NCT02947347
Diagnosis Type: Non-Hodgkins
USOR Number: 16176

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Arizona Oncology - Tucson

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

1845 W Orange Grove, Bldg 2
Tucson, Arizona 85704
P: (520) 531-8967

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Arizona Oncology - Phoenix

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

2222 E Highland Ave, Suite 400
Phoenix, Arizona 85016
P: (602) 277-4868

More Details View Practice Page

Pages